Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026

Boehringer Ingelheim Presents Positive Zongertinib PRO Data at ASCO 2026

Boehringer Ingelheim presented new data from its oncology clinical development program at the 2026 ASCO Annual Meeting. Key findings include positive patient-reported outcomes for HERNEXEOS® (zongertinib tablets) in HER2-mutant advanced non-small cell lung cancer (NSCLC), demonstrating improved physical functioning and reduced symptom burden. Early results also highlighted zongertinib's potential in other HER2-driven cancers, such as colorectal, esophageal, and breast cancers, showing encouraging clinical activity. Additionally, updated efficacy and safety data for obrixtamig, an investigational DLL3/CD3-targeting T-cell engager, in extensive-stage small cell lung cancer (ES-SCLC) revealed a confirmed objective response rate of 73%. These presentations underscore the company's commitment to advancing precision cancer care.

• New patient-reported outcomes (PRO) data from the Phase Ib Beamion LUNG-1 trial (NCT04886804) for zongertinib in HER2-mutant advanced NSCLC showed significant improvements in patients' physical functioning and NSCLC-related symptoms within one week of treatment, sustained over time. These PROs, assessed by EORTC QLQ-C30 and NSCLC-SAQ, further support the efficacy and safety data that led to the recent U.S. FDA accelerated approval for zongertinib in this indication.
• Early data demonstrated zongertinib's clinical activity beyond lung cancer, including in metastatic colorectal cancer (mCRC), metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC), and metastatic breast cancer (mBC). In mCRC, zongertinib monotherapy achieved a confirmed objective response rate (ORR) of 42% and a disease control rate (DCR) of 95%. In mGEAC and mBC, zongertinib in combination with agents like trastuzumab deruxtecan and trastuzumab emtansine showed encouraging responses and manageable safety profiles.
• Updated efficacy and safety results from the Phase I DAREON®-8 trial for obrixtamig, a DLL3/CD3 T-cell engager, in combination with standard-of-care induction therapy for first-line extensive-stage small cell lung cancer (ES-SCLC) (N=44) revealed promising efficacy. The confirmed ORR was 73% (7% complete response, 66% partial response), with a DCR of 91%. Median duration of response and median progression-free survival were not yet reached, with 6- and 9-month PFS rates of 78% and 62% respectively.

Unpacking HERNEXEOS® Trial Design and Endpoints in HER2-mutant NSCLC

Multiple pivotal trials have established the clinical development landscape for HER2-mutant NSCLC, ranging from phase 2 registration studies to real-world evidence analyses. These studies have employed diverse primary endpoints including objective response rate and progression-free survival, with patient populations primarily consisting of pre-treated metastatic disease. The trial designs span from single-arm studies evaluating novel antibody-drug conjugates to comparative analyses of combination therapeutic approaches.

• DESTINY-Lung01 utilized a multicenter, international phase 2 design with 91 patients receiving trastuzumab deruxtecan 6.4 mg/kg, employing objective response rate as the primary endpoint and achieving 55% centrally confirmed responses with median progression-free survival of 8.2 months

• IFCT 1703-R2D2 implemented a multicenter, non-randomized phase 2 study treating 45 patients with pertuzumab, trastuzumab, and docetaxel combination therapy, demonstrating 29% objective response rate and median progression-free survival of 6.8 months in platinum-refractory patients

• ATLAS real-world study prospectively evaluated 35 patients comparing chemotherapy versus HER2-targeted TKIs (afatinib, dacomitinib, pyrotinib) as first-line therapy, showing comparable median progression-free survival of 4.43 months for chemotherapy versus 4.65 months for TKIs

• Zongertinib named patient program collected real-world data from six consecutive patients previously treated with trastuzumab-deruxtecan, achieving clinical benefit in 100% of patients including one complete response in brain metastases with minimal toxicity profile

• European multicenter retrospective cohort analyzed 101 patients across 38 centers with HER2 exon-20 insertions, establishing median overall survival of 24 months as primary endpoint while demonstrating first-line chemotherapy response rates of 43.5%

• Recent combination therapy analysis evaluated 118 patients with next-generation sequencing-confirmed HER2 mutations, showing superior progression-free survival for combination regimens versus monotherapy (7.8 versus 5.3 months) with chemotherapy plus immunotherapy plus anti-angiogenic therapy achieving optimal 16.3-month progression-free survival

Addressing Unmet Needs in HER2-mutant Advanced NSCLC with Zongertinib

The landscape of HER2-mutant advanced NSCLC presents significant therapeutic challenges despite recent approvals of targeted agents. HER2 mutations occur in approximately 2-4% of NSCLC cases and have historically shown poor responses to standard treatments. While trastuzumab deruxtecan and novel tyrosine kinase inhibitors like zongertinib have emerged as approved options, substantial unmet needs persist across diverse patient populations and clinical scenarios.

• Treatment-resistant populations requiring alternatives to current therapies, including patients who develop resistance to existing HER2-targeted agents and those with severe interstitial lung disease following antibody-drug conjugate therapy

• Heavily pretreated patients with compromised performance status (ECOG ≥2), who represented 50% of patients in real-world cohorts and often have limited treatment options due to reduced tolerability of aggressive regimens

• Patients with brain metastases who need effective treatments with robust central nervous system penetration, as current therapies show mixed responses in addressing CNS disease

• Distinct HER2 mutation subtypes beyond tyrosine kinase domain alterations, including extracellular domain mutations (18-24% of cases) and transmembrane/juxtamembrane domain mutations (5-7% of cases), whose clinico-genomic characteristics remain largely unexplored

• Patients with complex genomic profiles including concomitant EGFR mutations and HER2 amplification requiring dual-targeted approaches, as well as those with HER2 amplification as an acquired resistance mechanism to EGFR tyrosine kinase inhibitors

• First-line treatment populations where standard of care remains chemotherapy with or without immunotherapy, highlighting the need for effective upfront targeted therapies in treatment-naive patients

Boehringer Ingelheim's Dual Oncology Momentum: HER2 and T-Cell Engagers

Boehringer Ingelheim's recent presentations at ASCO 2026 underscore a significant stride in advancing precision cancer care, particularly through the continued development of HERNEXEOS® (zongertinib) and the emerging T-cell engager, obrixtamig. Zongertinib, an oral, irreversible, and highly selective HER2 TKI, has already secured accelerated FDA approval for previously treated HER2-mutant NSCLC, addressing a critical unmet need where treatment options are limited and prognosis is often poor. The newly reported positive patient-reported outcomes for zongertinib are particularly impactful, highlighting not just tumor control but also a meaningful improvement in patients' physical functioning and a reduction in symptom burden. This holistic benefit is a key differentiator in a competitive landscape, offering a compelling value proposition for patients and clinicians alike.

Beyond NSCLC, zongertinib's potential is expanding. Early clinical activity observed in other HER2-driven cancers, such as colorectal, esophageal, and breast cancers, suggests a broader utility for this selective inhibitor. Ongoing basket trials are strategically designed to explore its efficacy across a range of HER2-altered solid tumors, indicating a clear path toward label expansion. However, this expansion will require rigorous validation in larger cohorts, especially given the diverse nature of HER2 alterations and the varying responses observed across different mutation types. The competitive environment, with existing approved therapies like trastuzumab deruxtecan, also means that zongertinib's unique profile—sparing EGFR and demonstrating a manageable safety profile without drug-related interstitial lung disease—must be consistently communicated and reinforced.

Adding to this momentum, the impressive 73% confirmed objective response rate for obrixtamig in extensive-stage small cell lung cancer represents a promising breakthrough in an aggressive disease with historically poor outcomes. This investigational DLL3/CD3-targeting T-cell engager highlights Boehringer Ingelheim's commitment to diversifying its oncology pipeline with novel mechanisms of action. Together, these advancements position the company as a formidable player in the evolving landscape of targeted therapies and immunotherapies, poised to address high unmet needs across multiple challenging cancer indications.